Vitamin supplements slow down the progression of glaucoma
Peer-Reviewed Publication
Updates every hour. Last Updated: 9-Jun-2025 18:09 ET (9-Jun-2025 22:09 GMT/UTC)
A vitamin supplement that improves metabolism in the eye appears to slow down damage to the optic nerve in glaucoma. Promising results have been published in the journal Cell Reports Medicine. The researchers behind the study have now started a clinical trial on patients.
Children born to mothers with obesity, gestational diabetes mellitus or a hypertensive disorder of pregnancy have higher systolic and diastolic blood pressure than children born to mothers without these risk factors, according to a new USC study. Among children whose mothers had at least one risk factor, blood pressure also rose more quickly between ages 2 and 18 compared to their peers. Researchers used data collected between January 1994 and March 2023 through the Environmental influences on Child Health Outcomes (ECHO) Program. The data include demographic and health information on 12,480 mother-child pairs from across the country, about half of whom identified as non-white. The study found that children born to mothers with at least one cardiometabolic risk factor had a systolic blood pressure (SBP) that averaged 4.88 percentile points higher than children whose mothers had no risk factors. Diastolic blood pressure (DBP) averaged 1.90 percentile points higher. Children born to mothers with two risk factors faced even higher blood pressure. For example, when mothers had both obesity and a hypertensive disorder of pregnancy, their children had SBP that averaged 7.31 points higher and DBP that averaged 4.04 points higher than children whose mothers had no risk factors.. The findings, which suggest that blood pressure interventions could start as early as pregnancy, were just published in JAMA Network Open.
The researchers discovered that while these T cell clones exist in both responsive and non-responsive patients, those who respond to immunotherapy exhibit a unique genetic signature within their T cell clones, and immunotherapy enhances their immune activity. Another key finding was that in non-responsive patients, certain T cell clones were simultaneously found both in the tumor and the bloodstream. The researchers concluded that for improved immune response, it is essential to activate T cell clones found only within the tumor, rather than those present in both the tumor and the blood.